MedTrace Logo

Rosuvastatin Pre-Treatment Influences the Risk of Coronary Intervention Study

NCT01378715 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2011-06-22

No results posted yet for this study

Summary

The aim of this study is to determine whether a pre-treatment with high-dose statin (one day prior and just before intervention, rosuvastatin 20mg/day) has a positive impact on the occurrence of periprocedural myocardial infarction during percutaneous coronary intervention (PCI).

Conditions

Interventions

DRUG

Rosuvastatin

Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).

Sponsors & Collaborators

  • University Hospital, Motol

    lead OTHER

Principal Investigators

  • Josef Veselka, Prof., MD · Dpt. of Cardiology, 2nd Medical School of Charles Universty and University Hospital Motol

  • David Zemanek, MD · Dpt. of Cardiology, 2nd Medical School of Charles Universty and University Hospital Motol

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-06-30
Completion
2012-08-31

Countries

  • Czechia
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01378715 on ClinicalTrials.gov